Core Network Partners Announced for CADTH’s Post-Market Drug Evaluation Network

CADTH is pleased to announce the 4 successful Core Network Partners of its inaugural Post-Market Drug Evaluation (PMDE) Network. Core Network Partners will be the foundation of the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space.  

The PMDE Program issued a request for proposals on February 1, 2022, for its Core Network Partners. Proposals were reviewed by a multidisciplinary review panel that identified the following 4 teams: 

• Alberta Drug and Technology Evaluation Consortium (ADTEC), led by Dr. Scott Klarenbach and hosted by the University of Alberta in Edmonton, Alberta.  
• Canadian Cancer Real-world Evaluation (CCRE), led by Dr. Kelvin Chan and hosted by Ontario Health – Cancer Care Ontario. 
• Canadian Network for Observational Drug Effect Studies (CNODES), led by Dr. Robert Platt and hosted by the Lady Davis Institute of the Jewish General Hospital in Montreal, Quebec.  
• The Knowledge Synthesis and Application Unit – Post-Market Drug Evaluation Team (KSAU-PODET), led by Drs. Melissa Brouwers and George Wells and hosted by the University of Ottawa. 

These 4 teams bring decades of experience in the post-market landscape and are well prepared to respond to the needs of federal, provincial, and territorial decision-makers.  

The PMDE Program will launch September 1, 2022, and Core Network Partner grants are set to begin at this time. The grants will be in effect for 3 years, ending August 31, 2025, pending contract execution with the host institutions.  

If you have any questions about the PMDE Program or Network, please contact infoPMDE@CADTH.ca.